A multicenter phase 1b randomized, placebo-controlled, blinded study to evaluate the safety, tolerability and efficacy of microbiome study intervention administration in combination with anti-PD-1 therapy in adult patients with unresectable or metastatic melanoma. This evidence concerns the gene PDCD1 and metastatic melanoma.